Spanish Intragastric Balloon Consensus Statement

• Published in: Revista española de enfermedades digestivas Vol. 115; no. 1; p. 22
• Main Authors: Arau, Roman Turro, Tornero, Maria Munoz, Bernal, Cristian Sierra, Ares, David Martinez, Fernandez, Jose Francisco Juanmartinena, Neto, Manoel Galvao, Artero, Laura Sanchis, Martinez, David Carral, Lopez, Jaime Bernabeu, Jimenez, Andres Serrano, Duran, Javier Nebreda, Rizo, Xavier Cortes, Valenciano, Carlos Marra-Lopez, Garcia, Andres J. del Pozo, Diez, Jesus Espinel, Grecco, Eduardo, Macian, Ramiro Carreno, Silva, Lyz Bezerra, Uso, Miguel Angel Escarti, Alvarado, Claudia Consiglieri, Vera, Javier Sola, Zulueta, Arnulfo Fernandez, Coll, Eduardo Espinet, Jimenez, Jose Luis Dominguez
• Format: Journal Article
• Language: Spanish
• Published: Sociedad Espanola de Patologia Digestivas 01-01-2023
• ISSN: 1130-0108

Background: intragastric balloons (IGBs) are a minimally invasive, increasingly popular option for obesity treatment. However, there is only one worldwide guideline standardizing the technical aspects of the procedure (BIBC, SOARD 2018). Objectives: to construct a practical guideline for IGB usage by reproducing and expanding the BIBC survey among the Spanish Bariatric Endoscopy Group (GETTEMO). Methods: a 140-question survey was submitted to all GETTEMO members. Twenty-one Spanish experienced endoscopists in IGBs answered back. Eight topics on patient selection, indications/contraindications, technique, multidisciplinary follow-up, results, safety, and financial/legal aspects were discussed. Consensus was defined when there was [greater than or equal to] 70% agreement. Results: overall data included 20 680 IGBs including 12 different models. Mean age was 42.0 years-old, 79.9 % were women, and the mean preoperative body mass index (BMI) was 34.05 kg/[m.sup.2]. Indication in BMI > 25 kg/[m.sup.2], 10 absolute contraindications, and nutritional and medication measures at follow-up were settled. A mean %TBWL (total body weight loss) of 17.66 % [+ or -] 2.5 % was observed. Early removal rate due to intolerance was 3.62 %. Adverse event rate was 0.70 % and 6.37 % for major and minor complications with consensual management. A single case of mortality occurred. IGBs were placed in private health, prior contract, and with full and single payment at the beginning. Seven lawsuits (0.034 %) were received, all ran through civil proceeding, and with favorable final resolution. Conclusions: this consensus based on more than 20 000 cases represents practical recommendations to perform IGB procedures. This experience shows that the device leads to satisfactory weight loss with a low rate of adverse events. Most results are reproducible compared to those obtained by the BIBC. Keywords: Consensus statement. Intragastric balloon. Obesity. Endoscopy. Bariatric endoscopy.